La cultura come bene comune

What happens if we look at culture as commons? My effort is to "capture" sense of culture as commons in an ever new "practice of everyday life" (De Certeau 2005). The aim of this paper is not to explore the concept of culture and commons, rather to investigate, through three good practices, the consequences that culture, seen as a common good, can bring to places. The three cases presented show what it means to invest in culture as a common asset and resource of difference. To manage culture as a common good, therefore, means investing in the revolutionary force of culture. It is possible to compare, in a certain sense, the revolutionary force of culture to the revolutionary demands of art recalled by Walter Benjamin. Benjamin hypothesizes the possibility of a political use of art

Donna e (è) scienza

Questo contributo analizza il ruolo della donna nella società in chiave positiva, per esplorare il binomio donna e (è) scienza, una “e” che unisce, ma anche e soprattutto una “e” che afferma e si fa verbo. Obiettivo è riflettere criticamente su alcuni degli stereotipi che ci ingabbiano, inconsapevolmente, quando parliamo di scienza, per focalizzare l’attenzione sul ruolo che la donna occupa nella società, non ascrivibile semplicemente all’ambito giuridico, visto che ragioni storiche e culturali talora limitano la fruizione dei diritti delle donne

Land.com. The art of becoming

This paper aims to bring a new imprint to social research by looking at places as communicative spaces, as "active metaphors" capable of transforming everything within them (their inhabitants) and of being, in turn, continuously transformed by the presence of humans. I want to explore what happens (or what can happen) when we look at places in their uniqueness to bring about empowerment. A dynamic model is outlined, to enable us to get to know and redesign places. What happens if we exploit their full potential? What happens when we are able to build a shared project starting from the recognition of each other’s strengths, and we are able to transform weaknesses into opportunities? Certainly, this may not be enough to transform places, but perhaps it can show us how to live better within them

Donna e (è) scienza

Questo contributo analizza il ruolo della donna nella società in chiave positiva, per esplorare il binomio donna e (è) scienza, una “e” che unisce, ma anche e soprattutto una “e” che afferma e si fa verbo. Obiettivo è riflettere criticamente su alcuni degli stereotipi che ci ingabbiano, inconsapevolmente, quando parliamo di scienza, per focalizzare l’attenzione sul ruolo che la donna occupa nella società, non ascrivibile semplicemente all’ambito giuridico, visto che ragioni storiche e culturali talora limitano la fruizione dei diritti delle donne

Aging changes complexity of heart rate dynamics assessed by entropy and Lyapunov exponent analysis

In recent years, many research groups are trying to quantify the physiological signals of an individual, proposing new models to assess the complex dynamics of biological control systems. Indeed, life coincides with the good handling of the structures in the organism and of physiological control mechanisms, while disease and death coincide with the loss of structure and of coordinated functions. The homeodynamic systems which normally govern health are the same that cause pathological events when activated inadequately, or rather, when the balance between order and chaos of the elementary physiological processes is no longer effectively controlled in relation to any type of stress, both external and internal to the body. In a complex system, loss or alteration of communication between physiological signals means pathology. In this paper a signal analysis method based on Entropy (E), Lyapunov exponent (1), Median Absolute Deviation (MAD), Multiscale Entropy (MSE), is proposed to estimate the complexity of long-range temporal correlation heart rate (HR) time series for an elderly person and a young person both healthy. These new methods could improve overall understanding of the physiological system of the human organism, by adopting new models and experimental paradigms, such as those of fractality and entropy, who have the ability to direct from an organ medicine to a modern systemic medicine

Being (past and present) President of the ERS: interview about the role, perspectives on career development, and vision for the Society

This article presents the views of the past and current Presidents of the ERS regarding their role, perspectives on career development and vision for the Society, along with important messages to inspire ECMs to build their own successful career. https://bit.ly/3kAvxIM

Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP

Preclinical data indicated a detrimental effect of statins on the anti-lymphoma activity of rituximab. We evaluated the impact of concomitant statin medication on the response and survival of patients with diffuse large B cell lymphoma (DLBCL) receiving rituximab-cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) as first-line therapy. Medical histories of patients with DLBCL who were treated with R-CHOP as first-line therapy were assessed for concomitant statin use, response after completion of chemotherapy, event-free survival (EFS), and overall survival (OS). Furthermore, 2-[18F]fluor-2-deoxyglucose (FDG)-PET/CT results after completion of first-line therapy were compared between the groups. Overall, 145 patients with DLBCL treated with R-CHOP from January 2001 to December 2009 were analyzed. Twenty-one (15%) patients received statins throughout therapy. Five-year EFS was 67.3% in patients without statins compared with 79% in patients receiving statins during R-CHOP (HR, 0.47; 95% CI, 0.15-1.54, p = 0.2). Five-year OS was 81.4% for patients without statins compared with 93.3% for patients taking statins (HR, 0.58; 95% CI 0.07-4.55, p = 0.6). There were no statistically significant differences in the rates of complete remissions between the two groups (75% in the non-statin group versus 86% in the statin group, p = 0.45). A trend toward a lower rate of complete metabolic responses in FDG-PET/CT after chemotherapy was seen in patients without statin medication compared with the patients taking statins (84% versus 92%, p = 0.068). Concomitant statin use had no adverse impact on response to chemotherapy, EFS, and OS in patients treated with R-CHOP for DLBC

Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim

To reduce the duration of neutropenia after conditioning chemotherapy and autologous peripheral blood stem cell transplantation (APBSCT), granulocyte-colony stimulating factors (G-CSF) are commonly administered. We retrospectively evaluated the impact of pegfilgrastim compared to filgrastim on neutrophil engraftment, hospital stay, and supportive measures in patients with multiple myeloma after conditioning with Melphalan 200 (Mel200) followed by APBSCT. Ninety-two APBSCT after Mel200 treatment were performed in 72 patients between January 2006 and December 2009 at our institution. Patients received either single-dose pegfilgrastim (n = 46; 50%), or daily filgrastim (n = 46; 50%) after APBSCT (median duration of filgrastim use, 9days; range, 3-14days). Duration of neutropenia grade IV was shorter with pegfilgrastim compared with filgrastim (median, 5days (range, 3-14days) versus 6days (range, 3-9days), p = 0.0079). The length of hospitalization differed significantly (pegfilgrastim (median, 14.5days; range, 11-47days) versus filgrastim (median, 15.5days; range, 12-64days), p = 0.024). Pegfilgrastim-treated patients had less red blood cell transfusions (median, 0 transfusions (range, 0-10) versus 0.5 transfusions (range, 0-9), p = 0.00065). Pegfilgrastim was associated with reduced cost of the treatment procedure compared with filgrastim (p = 0.031). Pegfilgrastim appears to be at least equivalent to filgrastim without additional expenditure in myeloma patients treated with Mel200 and APBSC

Thermal Modeling of NUHOMS HSM-15 and HSM-1 Storage Modules at Calvert Cliffs Nuclear Power Station ISFSI

As part of the Used Fuel Disposition Campaign of the Department of Energy (DOE), visual inspections and temperature measurements were performed on two storage modules in the Calvert Cliffs Nuclear Power Station’s Independent Spent Fuel Storage Installation (ISFSI). Detailed thermal models models were developed to obtain realistic temperature predictions for actual storage systems, in contrast to conservative and bounding design basis calculations